Stocks · News reference
Agomab Therapeutics Doses First Patient In NOV-ERA, Global Phase 2b Study Evaluating Ontunisertib In Patients With Symptomatic FSCD
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
Agomab Therapeutics reports positive 48-week Phase 2a trial data for ontunisertib in patients with fibrostenotic Crohn's disease.
Agomab Therapeutics Announces Results From 48-Week OLE Portion Of Its Phase 2A STENOVA Trial Evaluating Ontunisertib In Patients With Severe Crohn's Disease; Favorable Safety And Tolerability Profile Maintained Through Up To 60 Weeks Of Treatment; Low Annualized FSCD-Related Event Rate Of 3%